BR112023000308A2 - Uso de taurolidina contra vírus - Google Patents

Uso de taurolidina contra vírus

Info

Publication number
BR112023000308A2
BR112023000308A2 BR112023000308A BR112023000308A BR112023000308A2 BR 112023000308 A2 BR112023000308 A2 BR 112023000308A2 BR 112023000308 A BR112023000308 A BR 112023000308A BR 112023000308 A BR112023000308 A BR 112023000308A BR 112023000308 A2 BR112023000308 A2 BR 112023000308A2
Authority
BR
Brazil
Prior art keywords
taurolidine
present application
virus
viruses
research
Prior art date
Application number
BR112023000308A
Other languages
English (en)
Portuguese (pt)
Inventor
Gao Yuwei
Li Yuanguo
Lyu Chaoxiang
Su Zhong
Li Song
Wang Tiecheng
Zhong Wu
Xiang Haiyang
Sun Weiyang
Wang Xuefeng
Zhou Bo
Li Entao
Feng Na
Zhao Yongkun
Yang Songtao
Xia Xianzhu
Original Assignee
Acad Of Military Medical Sciences
Changchun Mailing Biological Eng Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010639186.0A external-priority patent/CN111773227A/zh
Priority claimed from CN202010638926.9A external-priority patent/CN111658652A/zh
Priority claimed from CN202010994928.1A external-priority patent/CN112641789A/zh
Application filed by Acad Of Military Medical Sciences, Changchun Mailing Biological Eng Co Ltd filed Critical Acad Of Military Medical Sciences
Publication of BR112023000308A2 publication Critical patent/BR112023000308A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023000308A 2020-07-06 2021-07-02 Uso de taurolidina contra vírus BR112023000308A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010639186.0A CN111773227A (zh) 2020-07-06 2020-07-06 牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用
CN202010638926.9A CN111658652A (zh) 2020-07-06 2020-07-06 牛磺罗定在制备抗冠状病毒药物中的应用
CN202010994928.1A CN112641789A (zh) 2020-09-21 2020-09-21 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用
PCT/CN2021/104197 WO2022007713A1 (zh) 2020-07-06 2021-07-02 牛磺罗定在抗病毒中的应用

Publications (1)

Publication Number Publication Date
BR112023000308A2 true BR112023000308A2 (pt) 2023-03-28

Family

ID=77998103

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000308A BR112023000308A2 (pt) 2020-07-06 2021-07-02 Uso de taurolidina contra vírus

Country Status (4)

Country Link
JP (1) JP2023533041A (zh)
CN (1) CN113491700B (zh)
BR (1) BR112023000308A2 (zh)
WO (1) WO2022007713A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917285B (zh) * 2022-04-06 2023-06-23 军事科学院军事医学研究院军事兽医研究所 一种多糖化合物在预防和治疗呼吸道病毒感染药物中的应用
CN115350181B (zh) * 2022-08-17 2023-12-29 吉林大学 一种小分子化合物在制备抗病毒感染的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608051B1 (en) * 1999-03-12 2003-08-19 Medpointe Healthcare Inc. Compositions and methods for treating blood
EA034193B1 (ru) * 2011-04-21 2020-01-15 Оригенис Гмбх Гетероциклические соединения в качестве ингибиторов киназ
HRP20220313T1 (hr) * 2014-12-19 2022-05-13 Geistlich Pharma Ag Procesi za pripremu spojeva sličnih oksatiazinu
AU2016315779B2 (en) * 2015-08-31 2022-04-21 Cormedix Inc. Delivery of active agents using nanofiber webs
CN111658652A (zh) * 2020-07-06 2020-09-15 长春迈灵生物工程有限公司 牛磺罗定在制备抗冠状病毒药物中的应用
CN112641789A (zh) * 2020-09-21 2021-04-13 军事科学院军事医学研究院军事兽医研究所 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用
CN111671758A (zh) * 2020-07-06 2020-09-18 长春迈灵生物工程有限公司 牛磺罗定在制备抗hiv病毒药物中的应用
CN111617086A (zh) * 2020-07-06 2020-09-04 长春迈灵生物工程有限公司 牛磺罗定在制备抗hpv病毒药物中的应用
CN111773227A (zh) * 2020-07-06 2020-10-16 长春迈灵生物工程有限公司 牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用

Also Published As

Publication number Publication date
CN113491700A (zh) 2021-10-12
JP2023533041A (ja) 2023-08-01
CN113491700B (zh) 2023-03-28
WO2022007713A1 (zh) 2022-01-13

Similar Documents

Publication Publication Date Title
BR112023000308A2 (pt) Uso de taurolidina contra vírus
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
BR112018075682A2 (pt) inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
UY39529A (es) Nuevos agentes antivirales derivados de espiropirrolidina
GT200800256A (es) Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BR112012013252A2 (pt) composição farmacêutica tópica, preservativo, composto, e, uso do mesmo
BRPI0508079A (pt) composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
BR112019022307A2 (pt) Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.
BR112022017209A2 (pt) Uso de composto nucleosídeo no tratamento de doenças infecciosas por coronavírus
BR112021024001A2 (pt) Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
Paull et al. Astodrimer sodium, dendrimer antiviral, inhibits replication of SARS-CoV-2 in vitro
BR112022013741A2 (pt) Composição farmacêutica
BRPI0514768A (pt) composição farmacêutica, métodos para evitar ou tratar uma doença ou condição médica hepática em um indivìduo, para inibir a proliferação de células estreladas hepáticas, para seletivamente matar as células estreladas hepática, para inibir a expressão do antìgeno de superfìcie do vìrus da hepatite b em um mamìfero, e para evitar ou tratar fibrose ou inflamação em um mamìfero, e, uso de graptopetalum ou echeveria
BR112023025738A2 (pt) Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
BR112022015046A2 (pt) Uso de forsitina e/ou seus derivados, método para a inibição da proteína 3clpro do vírus covid-19, uso de composição de forsitina/forsitosídeo, métodos para uso contra o vírus covid-19 ou para o tratamento de doenças causadas pelo vírus covid-19, composição de forsitina/forsitosídeo e medicamento compreendendo uma composição de forsitina/forsitosídeo
BR112022019357A2 (pt) Medicamento/agente para o tratamento de coronavírus, infecções retrovirais e hepatite c
BR112014004339A2 (pt) suspensão oral
MX2015011347A (es) Tratamiento sistemico y topico combinado de tejidos con trastorno.